摘要:
A method of modulating energy homeostasis in a mammal without eliciting a sexual response by administration of a therapeutically effective amount of a pharmaceutical composition including a melanocortin receptor compound of the formula: where R1 is a bond or a linker unit including from one to six backbone atoms and an unsubstituted naphthalene group, and L, R2, R3 and Rx are as defined in the specification.
摘要翻译:一种通过施用治疗有效量的药物组合物来调节哺乳动物的能量稳态的方法,其不引起性反应,所述药物组合物包括下式的黑皮质素受体化合物:其中R 1是键或连接基 包含1至6个骨架原子和未取代的萘基的单元,以及L,R 2,R 3和R x x定义如 规格。
摘要:
A highly selective melanocortin-4 receptor antagonist cyclic hexapeptide of the formula where R1, R2, R3a, R3b, R4, R5, x, y and z are as defined in the specification, and a method of treating body weight disorders, including cachexia, sarcopenia and wasting syndrome or disease, and treating inflammation and immune disorders.
摘要翻译:具有下式的高选择性黑皮质素-4受体拮抗剂环状六肽其中R 1,R 2,R 3a,R 3b, R 3,R 5,R 5,x,y和z如说明书中所定义,以及治疗体重紊乱的方法,包括恶病质,肌肉减少症和 浪费综合征或疾病,以及治疗炎症和免疫疾病。
摘要:
A highly selective melanocortin-4 receptor antagonist cyclic peptide of the formula where R1, R2, R3, R4a, R4b, R5, R6, R7, x, y and z are as defined in the specification, and a method of treating body weight disorders, including cachexia, sarcopenia and wasting syndrome or disease, and treating inflammation and immune disorders.
摘要:
There is provided compounds having the formula of structure I: wherein the groups —C(R8)(CH2)vCH(R9)(CH2)y-Q and —C(R8)(CH2)vCH(R9)(CH2)y-J are the same, and R1a, R1b, R2a, R2b, R8, R9, J, Q, W, X, L2, v and y have meanings given in the description. Thus use of such compounds in the treatment of a condition responsive to changes in melanocortin receptor function in a human or non-human mammal (e.g. male sexual dysfunction, female sexual dysfunction, an eating disorder, above optimal body weight, obesity, below-optimal body weight or cachexia) is also described.
摘要翻译:提供具有结构式I的化合物:其中基团-C(R 8)(CH 2)2 CH(R' (CH 2)n(CH 2)n(CH 2)q(CH 2) (CH 2))CH(R 9)(CH 2)n Y -J相同,和 R 1a,R 1b,R 2a,R 2b,R 8,R 8, R 9,J,Q,W,X,L 2,v和y具有在说明书中给出的含义。 因此,使用这些化合物治疗对人或非人哺乳动物(例如男性性功能障碍,女性性功能障碍,进食障碍,超过最佳体重,肥胖,低于最佳)的黑色素皮质素受体功能变化的病症 体重或恶病质)也被描述。
摘要:
Melanocortin receptor-specific compounds of the general formulas and pharmaceutically acceptable salts thereof, where J is a substituted or unsubstituted monocyclic or bicyclic ring structure, L is a linker, W is a heteroatom unit with at least one cationic center, hydrogen bond donor or hydrogen bond acceptor, Q includes a substituted or unsubstituted aromatic carbocyclic ring, R6, R7, y and z are as defined in the specification, and the carbon atom marked with an asterisk can have any stereochemical configuration, and optionally with one or two additional ring substituents as defined, which compounds bind to one or more melanocortin receptors and are optionally an agonist, a partial agonist, an antagonist, an inverse agonist or an antagonist of an inverse agonist, and may be employed for treatment of one or more melanocortin receptor-associated conditions or disorders, and methods for the use of the compounds of the invention.
摘要:
Melanocortin receptor-specific pyrrolidine compounds having the structure: and stereoisomer and pharmaceutically acceptable salts thereof, where R1, R2, and R3 are as described in the specification, preferably where R3 is a D-amino acid with at least one substituted or unsubstituted phenyl or naphthyl aromatic ring, and where R3 optionally further includes an amine capping group or from one to three additional amino acid residues, optionally with an amine capping group, which compounds are agonists, antagonists or mixed agonists and antagonists at one or more melanocortin receptors, and having utility in the treatment of melanocortin receptor-related disorders and conditions. Methods of synthesis of compounds of structure (I), pharmaceutical compositions containing a compound of structure (I) and methods relating to the use thereof are also disclosed.
摘要:
Metallopeptides are provided for use in treatment of sexual dysfunction in mammals. The metallopeptides are agonists for at least one of melanocortin-3 or melanocortin-4 receptors. The metallopeptides are conformationally fixed on complexation of a metal ion-binding portion thereof with a metal ion. Also provided are metallopeptides that are antagonists for at least one of melanocortin-3 or melanocortin-4 receptors.
摘要:
A peptide of the structural formula: or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, m and n are as defined. Further provided are methods for treatment of sexual dysfunction, including erectile dysfunction and female sexual dysfunction, and combination drugs and method of use thereof, including a peptide of the invention and one or more second sexual dysfunction pharmaceutical agents.
摘要翻译:一种结构式的肽或其药学上可接受的盐,其中R 1,R 2,R 3,R 4 R 5,R 6,m和n如上所定义。 还提供了治疗性功能障碍的方法,包括勃起功能障碍和女性性功能障碍,以及联合药物及其使用方法,包括本发明的肽和一种或多种第二性功能障碍药剂。
摘要:
Linear and cyclic peptides are provided specific to one or melanocortin receptors, and which exhibit agonist, antagonist, or mixed agonist-antagonist activity. In one embodiment, a linear peptide of the following general formula is provided:
摘要:
A cyclic peptide with a C-terminus —OH group. Further provided are compositions and methods for treatment of sexual dysfunction in mammals, including male sexual dysfunction, such as erectile dysfunction, and female sexual dysfunction, by administration of a cyclic peptide including a C-terminus —OH group. Methods of administration include injection, oral, urethral, vaginal, nasal and mucosal administration.